hrs4r
 I want to donate

The Precision Oncology research group in Girona (OncoGiR_Pro) is made up of researchers who are members of the ICO Girona Medical Oncology Service and collaborators from other services, located at the Hospital Dr. Josep Trueta. Led by Dr. Joaquim Bosch, the research group's mission is to integrate clinical, epidemiological and translational research in the field of precision oncology. The aim is to develop new therapeutic strategies and identify biomarkers for predicting the risk and clinical course of various cancers.

Main lines of research
  • Clinical development of new drugs, biomarkers for predicting response to treatment and clinical evolution, genetic basis of hereditary cancer, cancer risk prediction models.

These lines of research apply to different tumours: breast, digestive, thoracic, urological, skin, ENT and gynaecological.

Strategic objectives
  • Mission: To integrate clinical, epidemiological and translational research in the field of precision oncology.
  • Goal: To develop new therapeutic strategies and identify biomarkers for the prediction of risk and clinical evolution of different cancers.
Publications
Tavira B, Iscar T, Manso L, Santaballa A, Gil-Martin M, García García Y, Romeo M, Iglesias M, de Juan Ferré A, Barretina-Ginesta MP, Manzano A, Gaba L, Rubio MJ, de Andrea CE, González-Martín A

Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).

CLINICAL CANCER RESEARCH, 2024, 30, 176-186 dx.doi.org/10.1158/1078-0432.CCR-23-0771
Gonzalez-Abuin N, Pons T, Fuster T, Quintana I, Terradas M, Aiza G, Brunet J, Capellá G, Hampel H, Valle L

Lack of evidence for germline WWP1 pathogenic variants in gastrointestinal polyposis and other phenotypes suggestive of PTEN-hamartoma-tumor syndrome.

Genes and Diseases, 2024, 11, 524-527 dx.doi.org/10.1016/j.gendis.2023.03.011
Mostaghim A, Minkove S, Aguilar-Company J, Ruiz-Camps I, Eremiev-Eremiev S, Dettorre GM, Fox L, Tondini C, Brunet J, Carmona-García M, Lambertini M, Bower M, Newsom-Davis T, Sharkey R, Pria AD, Rossi M, Plaja A, Salazar R, Sureda A, Prat A, Michalarea V, Van Hemelrijck M, Sita-Lumsden A, Bertuzzi A, Rimassa L, Rossi S, Rizzo G, Pedrazzoli P, Lee AJ, Murphy C, Belessiotis K, Diamantis N, Mukherjee U, Pommeret F, Stoclin A, Martinez-Vila C, Bruna R, Gaidano G, D'Avanzo F, Gennari A, Athale J, Eichacker P, Pinato DJ, Torabi-Parizi P, Cortellini A, OnCovid study group.

Prior immune checkpoint inhibitor (ICI) therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2024, 139, 13-20 dx.doi.org/10.1016/j.ijid.2023.11.021
Candal-Pedreira C, Ruano-Ravina A, Calvo de Juan V, Cobo M, Trigo JM, Rodríguez-Abreu D, Estival A, Carcereny E, Cucurull M, López Castro R, Medina A, García Campelo R, Cordeiro González P, Sánchez-Gastaldo A, Bosch-Barrera J, Massutí B, Dómine M, Camps C, Ortega AL, Sánchez-Hernández A, Guirado Risueño M, Del Barco Morillo E, Garrido Fernández A, Provencio M

Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients.

ARCHIVOS DE BRONCONEUMOLOGIA, 2024, 60, 88-94 dx.doi.org/10.1016/j.arbres.2023.12.005
Vincenzi B, Cortellini A, Mazzocca A, Orlando S, Romandini D, Aguilar-Company J, Ruiz-Camps I, Valverde Morales C, Eremiev-Eremiev S, Tondini C, Brunet J, Bertulli R, Provenzano S, Bower M, Generali D, Salazar R, Sureda A, Prat A, Vasiliki M, Van Hemelrijck M, Sita-Lumsden A, Bertuzzi A, Rossi S, Jackson A, Grosso F, Lee AJX, Murphy C, Belessiotis K, Mukherjee U, Pommeret F, Loizidou A, Gaidano G, Dettorre GM, Grisanti S, Tucci M, Fulgenzi CAM, Gennari A, Napolitano A, Pinato DJ

Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16 dx.doi.org/10.1177/17588359231225028
Pardo-Cea MA, Farré X, Esteve A, Palade J, Espín R, Mateo F, Alsop E, Alorda M, Blay N, Baiges A, Shabbir A, Comellas F, Gómez A, Arnan M, Teulé A, Salinas M, Berrocal L, Brunet J, Rofes P, Lázaro C, Conesa M, Rojas JJ, Velten L, Fendler W, Smyczynska U, Chowdhury D, Zeng Y, He HH, Li R, Van Keuren-Jensen K, de Cid R, Pujana MA

Biological basis of extensive pleiotropy between blood traits and cancer risk.

GENOME MEDICINE, 2024, 16, 21-21 dx.doi.org/10.1186/s13073-024-01294-8
Fortuno C, Feng BJ, Carroll C, Innella G, Kohlmann W, Lázaro C, Brunet J, Feliubadaló L, Iglesias S, Menéndez M, Teulé A, Ballinger ML, Thomas DM, Campbell A, Field M, Harris M, Kirk J, Pachter N, Poplawski N, Susman R, Tucker K, Wallis M, Williams R, Cops E, Goldgar D, kConFab Investigators, James PA, Spurdle AB

Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum.

JCO Precision Oncology, 2024, 8 dx.doi.org/10.1200/PO.23.00453
Marruecos Querol J, Jurado-Bruggeman D, Lopez-Vidal A, Mesía Nin R, Rubió-Casadevall J, Buxó M, Eraso Urien A

Contouring aid tools in radiotherapy. Smoothing: the false friend.

CLINICAL & TRANSLATIONAL ONCOLOGY, 2024 dx.doi.org/10.1007/s12094-024-03420-9
Pla H, Felip E, Obadia V, Pernas S, Viñas G, Margelí M, Fort-Culillas R, Del Barco S, Sabaté N, Fort E, Lezcano C, Cirauqui B, Quiroga V, Stradella A, Gil Gil M, Esteve A, Recalde S

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort.

CLINICAL & TRANSLATIONAL ONCOLOGY, 2024 dx.doi.org/10.1007/s12094-024-03399-3
Hendricks LAJ, Hoogerbrugge N, Mensenkamp AR, Brunet J, Lleuger-Pujol R, Høberg-Vetti H, Haavind MT, Innella G, Turchetti D, Aretz S, Spier I, Tischkowitz M, Jahn A, Links TP, Olderode-Berends MJW, Blatnik A, Leter EM, Evans DG, Woodward ER, Steinke-Lange V, Anastasiadou VC, Colas C, Villy MC, Benusiglio PR, Gerasimenko A, Barili V, Branchaud M, Houdayer C, Tesi B, Yazicioglu MO, van der Post RS, Schuurs-Hoeijmakers JHM, PTEN Study Group, Vos JR

Cancer risks by sex and variant type in PTEN Hamartoma Tumor Syndrome.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115, 93-103 dx.doi.org/10.1093/jnci/djac188
Competitive projects
Codi oficial: CI23-20369 Start date:30/10/2023 Data fi: 30/10/2025 Investigador/a principal: ADELAIDA GARCIA VELASCO Organisme finançador: FUND. BANCARIA "LA CAIXA"
Codi oficial: biomarcador pan-cáncer Start date:19/10/2020 Data fi: 01/12/2024 Investigador/a principal: JOAN BRUNET VIDAL Organisme finançador: FUND. SEOM
Codi oficial: Inestabilidad de microsatélites con alta sensibilidad Start date:28/04/2023 Data fi: 27/04/2025 Investigador/a principal: JOAN BRUNET VIDAL Organisme finançador: FUND. SEOM
Codi oficial: 101095483 Start date:01/01/2023 Data fi: 31/12/2025 Investigador/a principal: JOAN BRUNET VIDAL Organisme finançador: EUROPEAN COMISSION
Codi oficial: Pfizer 2019 Joaquim Bosch Start date:05/07/2019 Data fi: 31/12/2024 Investigador/a principal: JOAQUIM BOSCH BARRERA, JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: PFIZER, S.L.U.
Job offers

Team

If you are a researcher and you are interested in collaborating with any of our research groups, please fill in this form.
I am interested in
If you are a student or you want to do an internship with any of our research groups, please fill in this form.
I am interested in

About IDIBGI!

menu